Daniel Olsen, DO
Urology · Dakota Dunes, SDNPI 1366973950
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,645 of the $3,285 with a category attached, or 80.5%. It is spread thinly across 31 manufacturers, the largest accounting for just 20.4% — the pattern of someone who eats at a lot of different presentations.
Across 95 payments — averaging $34.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$672
- Axonics, Inc.$591
- Boston Scientific$464
- Urogen Pharma, Inc.$217
- Sumitomo Pharma America, Inc.$173
- Histosonics, Inc.$171
- plus $998 from 25 others
What the payments were for
- Consulting fees$64019%
- Food & beverage$2,64581%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 3 | $672 |
| Axonics, Inc. | 11 | $591 |
| Boston Scientific | 16 | $464 |
| Urogen Pharma, Inc. | 6 | $217 |
| Sumitomo Pharma America, Inc. | 9 | $173 |
| Histosonics, Inc. | 1 | $171 |
| Calyxo, Inc. | 2 | $150 |
| AbbVie | 4 | $85 |
| Myriad Genetic Laboratories, Inc. | 4 | $66 |
| Myovant Sciences Inc. | 3 | $59 |
| Pfizer | 4 | $58 |
| Johnson & Johnson | 4 | $57 |
| Merck | 3 | $56 |
| Foundation Medicine, Inc. | 3 | $55 |
| Tolmar, Inc. | 3 | $53 |
| Bayer | 2 | $42 |
| Medtronic | 1 | $41 |
| Telix Pharmaceuticals | 2 | $35 |
| Coloplast | 2 | $32 |
| AstraZeneca | 1 | $23 |
| Teleflex LLC | 1 | $21 |
| E.r. Squibb & Sons, L.L.C. | 1 | $18 |
| Astellas Pharma US Inc | 1 | $18 |
| 180 Medical, Inc. | 1 | $18 |
| Accord Healthcare, Inc. | 1 | $18 |
| Argon Medical Devices, Inc. | 1 | $18 |
| Ferring Pharmaceuticals Inc. | 1 | $17 |
| Kowa Pharmaceuticals America, Inc. | 1 | $16 |
| Tolmar Pharmaceuticals, Inc. | 1 | $15 |
| Endo Pharmaceuticals Inc. | 1 | $14 |
| Sun Pharmaceutical Industries Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GILENYA$600
- Axonics$395
- CVAC Aspiration System$137
- JELMYTO$125
- LithoVue$125
How this compares
$3,285 in reported general payments places this provider in the 85th percentile of 40 urology providers in South Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 19 | $265,301 |
| OrgovyxRelugolix | 27 | $69,221 |
| Abiraterone Acetate | 35 | $58,090 |
| MyrbetriqMirabegron | 107 | $40,247 |
| Oxybutynin Chloride ErOxybutynin Chloride | 205 | $3,286 |
| Estradiol | 26 | $2,071 |
| Tamsulosin Hcl | 213 | $1,887 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 35 | $619 |
| Finasteride | 56 | $470 |
| Oxybutynin Chloride | 50 | $425 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 14 | $349 |
| Cephalexin | 46 | $201 |
| Prednisone | 35 | $155 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 42 | $137 |
| Ciprofloxacin Hcl | 23 | $77 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $18 | $305,549126 claims |
| Sumitomo Pharma America, Inc.Orgovyx | $173 | $69,22127 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 40 urology providers in South Dakota.
Other urology in Dakota Dunes
- Andrew BourneDakota Dunes$6K
- Jamie OlsenDakota Dunes$4K
- David DanielsDakota Dunes$3K
- Adam AlthausDakota Dunes$3K
- Timothy KneibDakota Dunes$3K
- Patrick HonnerDakota Dunes$1K
- Kenneth McCallaDakota Dunes$143
- John WolpertDakota Dunes$95
- David HowardDakota Dunes$83
- Patrick WalshDakota Dunes$53
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.